Role of optimal medication given to patients with hypertension and ischemic heart disease prior to an acute coronary syndrome
Abstract
Overview
Introduction.
Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and
ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.
The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or
IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).
Methods.
The study was carried out retrospectively and included patients admitted with a first episode of ACS
between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP +
IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-
ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.
Results.
This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A – 53%, and 515 patients in subgroup B – 47%. Total cardiac mortality was 9.98%, different depending
on the groups and subgroups studied: HBP group total – 7%, subgroup A – 5.1%, significantly lower compared
to subgroup B – 9.4% (p = 0.05); IHD group total – 12.2%, subgroup A – 9.07%, significantly lower compared to
subgroup B – 15.8% (p = 0.05); HBP + IHD group total – 14.35%, subgroup A – 9.9%, significantly lower compared
to subgroup B – 18.8% (p = 0.05).
Conclusions.
The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital
cardiac mortality among patients who develop a first-episode ACS.
Keywords
Acute coronary syndrome, Cardiac mortality, Hypertension, Ischemic heart disease, Optimal cardio – vascular medication
Article Information
Disclosure
Financial support: No grants or funding have been received for this study.
Correspondence
Călin Pop George Cosbuc Street nr 31 Baia Mare, Romania medicbm@yahoo.com
Further Resources
Trending Topic
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
